News, Short Squeeze, Breakout and More Instantly...
LUND, SWEDEN / ACCESSWIRE / July 22, 2024 / BioInvent International (STO:BINV) Two posters to be presented on early clinical projects from BioInvent's robust pipeline totaling six clinical programs: Progress with the Phase 1 trial studying BI-1910 as single agent in solid tumors Initial...
LUND, SE / ACCESSWIRE / July 17, 2024 / BioInvent International (STO:BINV) Agreement to support expansion of BI-1607 program with new Phase 2 triplet combination study in metastatic melanoma The study will evaluate anti-FcγRIIB antibody BI-1607 with low-dose anti-CTLA-4, ipilimu...
Model-informed approach supporting dose selection and optimization of clinical development Confirming wide potential dose-range of BI-1808 in the continued clinical evaluation which already has shown promising single agent safety and efficacy Poster to be presented at PAGE 2024 to be ...